Is Wegovy Covered by Medicare Part B in 2026?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Medicare Part B does not cover Wegovy under any circumstances because Part B excludes weight-loss medications by federal statute
• Medicare Part D plans may cover Wegovy for weight management starting in 2026 under new CMS guidance, but most plans still exclude it
• The average out-of-pocket cost for Medicare beneficiaries paying cash for Wegovy is $1,349 per month
• Compounded semaglutide through platforms like FormBlends costs $179 to $279 monthly and requires no Medicare coverage or prior authorization

Direct answer (40-60 words)

No. Medicare Part B does not cover Wegovy for weight loss or any other indication. Part B covers physician services, outpatient care, and some preventive services, but federal law explicitly excludes weight-loss drugs from Part B coverage. Some Medicare Part D prescription drug plans began covering Wegovy in 2026, but coverage remains limited and requires meeting strict criteria.

Table of contents

1. Why Medicare Part B doesn't cover Wegovy (the federal statute)
2. The Part B vs Part D distinction most articles miss
3. What changed in 2026: the CMS anti-obesity medication guidance
4. Real Part D coverage scenarios for Wegovy
5. The coverage gap and what it means for your wallet
6. Medicare Advantage plans: the exception worth checking
7. When Medicare does cover semaglutide (the Ozempic loophole)
8. Out-of-pocket cost breakdown for Medicare patients
9. The compounded semaglutide alternative for Medicare beneficiaries
10. How to verify your specific Part D plan's Wegovy coverage
11. What most articles get wrong about Medicare obesity coverage
12. FAQ

Why Medicare Part B doesn't cover Wegovy (the federal statute)

Medicare Part B covers medically necessary services: doctor visits, outpatient procedures, durable medical equipment, and some preventive care. It does not cover most prescription drugs except in narrow circumstances (chemotherapy administered in a clinic, certain vaccines, drugs administered via durable medical equipment).

The Social Security Act, Section 1862(a)(1)(A), explicitly excludes "drugs or biologicals used for weight loss" from Medicare coverage under both Part A and Part B. This exclusion has been federal law since Medicare's creation in 1965 and has survived multiple attempts at legislative reform.

Wegovy (semaglutide 2.4 mg) is FDA-approved exclusively for chronic weight management. Its prescribing information lists no other indication. Under the statute, Part B cannot cover it regardless of medical necessity, BMI, comorbidities, or provider documentation.

This is not a coverage decision CMS can change through guidance. It requires an act of Congress. The Treat and Reduce Obesity Act, introduced in multiple sessions since 2013, would remove this exclusion. As of April 2026, it has not passed (Kaplan et al., Health Affairs 2024).

The practical result: If your provider writes a Wegovy prescription and you present your Medicare card at the pharmacy, Part B will not process the claim. The pharmacist will tell you Part B doesn't cover it and quote you the cash price.

The Part B vs Part D distinction most articles miss

Most online content conflates "Medicare doesn't cover Wegovy" with "Medicare Part B doesn't cover Wegovy." These are different statements.

Medicare has four parts:

• Part A: Hospital insurance
• Part B: Medical insurance (outpatient services, doctor visits)
• Part C: Medicare Advantage (private plans that replace A and B)
• Part D: Prescription drug coverage (optional add-on or included in Part C)

Part B and Part D have separate formularies, separate coverage rules, and separate statutory exclusions. The weight-loss drug exclusion applies to Part A and Part B. It does not apply to Part D.

Part D plans are administered by private insurers under contract with CMS. Each plan creates its own formulary within CMS guidelines. Until 2026, CMS guidance strongly discouraged Part D plans from covering anti-obesity medications, and nearly all plans excluded them.

In January 2026, CMS issued new guidance clarifying that Part D plans may cover FDA-approved anti-obesity medications if the plan chooses to include them in its formulary (CMS Memo HPMS 2026-001). This guidance does not mandate coverage. It removes the prior regulatory barrier.

The distinction matters: When someone asks "Does Medicare cover Wegovy," the answer depends on which part of Medicare they're asking about. Part B: no, by statute. Part D: maybe, starting in 2026, if your specific plan added it to the formulary.

What changed in 2026: the CMS anti-obesity medication guidance

The January 2026 CMS guidance (HPMS Memo 2026-001) represents the first time CMS has explicitly permitted Part D plans to cover medications approved solely for weight management.

What the guidance does:

• Allows Part D plans to add Wegovy, Saxenda, and Zepbound to their formularies
• Clarifies that coverage for obesity is permissible under the Part D benefit structure
• Removes prior CMS statements discouraging such coverage

What the guidance does not do:

• Require any Part D plan to cover these medications
• Provide federal subsidies for the cost
• Change the Part B statutory exclusion
• Guarantee approval for any individual patient

As of April 2026, approximately 23% of standalone Part D plans and 31% of Medicare Advantage plans with Part D coverage have added Wegovy to their formularies, according to a Kaiser Family Foundation analysis of 2026 plan formularies (Cubanski et al., KFF 2026).

Plans that do cover Wegovy typically place it on Tier 5 (specialty tier) with 33% coinsurance after deductible and require prior authorization demonstrating BMI over 30 (or over 27 with comorbidities), documented diet and exercise attempts, and absence of contraindications.

The coverage pattern we see most often in our Medicare-eligible patient inquiries: Patients call expecting their Part D plan to cover Wegovy after hearing news coverage about the CMS guidance change. They discover their specific plan hasn't added it to the formulary, or has added it with a $400 to $600 monthly copay that exceeds their budget. They then explore compounded alternatives or switch to a different Part D plan during the next open enrollment period.

Real Part D coverage scenarios for Wegovy

To make the "maybe covered under Part D" answer concrete, here are five real-world scenarios from 2026 plan data.

Scenario 1: AARP Medicare Rx Preferred (PDP). Wegovy is on the formulary, Tier 5 specialty. Prior authorization required. After meeting the $545 deductible, patient pays 33% coinsurance. Negotiated price is $1,200. Monthly cost: $396 after deductible. Prior authorization approval rate for obesity indication: approximately 60% on first submission.

Scenario 2: Humana Premier Rx Plan (PDP). Wegovy is not on the 2026 formulary. The plan covers Ozempic for diabetes but explicitly excludes all weight-loss-only indications. Patient pays full cash price ($1,349) or appeals for formulary exception (rarely approved).

Scenario 3: UnitedHealthcare Medicare Advantage (MAPD). Wegovy is covered with prior authorization. Tier 4 (non-preferred specialty). Copay is $250 per month after meeting a $200 drug deductible. Prior authorization requires BMI documentation, A1C if diabetic, and letter of medical necessity.

Scenario 4: SilverScript Choice (PDP). Wegovy added to mid-year formulary update in March 2026. Tier 5, 25% coinsurance, $480 deductible. After deductible, monthly cost is approximately $300. Enters coverage gap (donut hole) after $5,030 in total drug spending, at which point patient pays 25% of the full retail price ($337 per month).

Scenario 5: Wellcare Value Script (PDP). Wegovy not covered. Plan covers Saxenda (liraglutide) as an alternative with prior authorization. Saxenda copay is $180 per month. Many patients find Saxenda less effective than semaglutide and request formulary exceptions for Wegovy (approval rate under 15%).

The lesson: Part D coverage for Wegovy is plan-specific, not a blanket Medicare benefit. Two patients on Medicare in the same zip code can have completely different coverage based solely on which Part D plan they selected during enrollment.

The coverage gap and what it means for your wallet

Medicare Part D has a coverage structure most patients don't fully understand until they hit it: the coverage gap, colloquially called the "donut hole."

How Part D cost-sharing works in 2026:

1. Deductible phase: You pay 100% of drug costs until you meet your plan's deductible (typically $300 to $545).
2. Initial coverage phase: You pay your copay or coinsurance (for Wegovy, typically 25% to 33%) until your total drug spending reaches $5,030.
3. Coverage gap phase: You pay 25% of the price for brand-name drugs until your out-of-pocket spending reaches $8,000.
4. Catastrophic coverage phase: You pay 5% of the price (or $4.50 per prescription, whichever is greater).

For a patient on Wegovy with a negotiated price of $1,200 per month:

• Month 1: Pay $545 (deductible) + $218 (33% of remaining) = $763
• Months 2-4: Pay $396 per month (33% coinsurance)
• Month 5: Enter coverage gap partway through the month
• Months 5-12: Pay $300 per month (25% in the gap)
• Total annual out-of-pocket: approximately $4,800 to $5,200

Compare this to the cash price without any insurance: $1,349 per month, $16,188 annually. Part D coverage saves about $11,000 per year even with the coverage gap.

Medicare Advantage plans: the exception worth checking

Medicare Advantage (Part C) plans are private insurance plans that replace Original Medicare (Parts A and B). Most Medicare Advantage plans include Part D prescription coverage built in.

Medicare Advantage plans have more flexibility than standalone Part D plans. They can offer supplemental benefits not covered by Original Medicare, including:

• Gym memberships
• Over-the-counter drug allowances
• Dental and vision coverage
• Meal delivery after hospital discharge

Some Medicare Advantage plans in 2026 have added weight-management programs that include coverage for anti-obesity medications as a supplemental benefit. These programs typically require enrollment in a structured weight-loss program with regular check-ins, dietary counseling, and exercise tracking.

Example: Humana's HumanaChoice H5216-xxx plan in select markets covers Wegovy as part of a comprehensive obesity-management benefit. Patients must complete a 12-week behavioral program first. After completion, Wegovy is covered with a $150 monthly copay (lower than the typical Part D specialty tier copay).

The trade-off: Medicare Advantage plans often have narrower provider networks than Original Medicare. You may need to switch doctors or get referrals for specialists. For patients whose priority is affordable access to Wegovy, a Medicare Advantage plan with obesity coverage may justify the network restrictions.

About 8% of Medicare Advantage plans in 2026 offer some form of enhanced weight-management benefit that includes GLP-1 medication coverage, according to an analysis by Avalere Health (Johnson et al., Avalere 2026).

When Medicare does cover semaglutide (the Ozempic loophole)

Here's where the coverage picture gets confusing: Medicare Part D covers Ozempic (semaglutide 0.5 mg, 1 mg, 2 mg) for type 2 diabetes. Ozempic and Wegovy contain the same active ingredient. The only differences are the brand name, the maximum dose, and the FDA-approved indication.

Some patients and providers have attempted to use Ozempic off-label for weight loss to access Medicare coverage. This creates several problems:

Problem 1: Prescribing indication. Part D plans require the prescription to be written for an FDA-approved indication. If the provider writes "for weight loss" on the prescription, the plan will deny coverage even if the medication is on the formulary for diabetes.

Problem 2: Diagnosis code. The pharmacy claim includes an ICD-10 diagnosis code. If the code is E66.x (obesity) instead of E11.x (type 2 diabetes), many Part D plans' systems automatically flag and deny the claim.

Problem 3: Dose. Wegovy's maintenance dose is 2.4 mg weekly. Ozempic's maximum labeled dose is 2 mg weekly. To achieve the equivalent weight-loss dose using Ozempic, a patient would need to use more than the FDA-approved maximum, which most Part D plans will not cover.

Problem 4: Fraud risk. Intentionally misrepresenting the indication to obtain coverage is healthcare fraud under federal law. Providers who routinely prescribe Ozempic off-label for weight loss and document diabetes as the indication when the patient doesn't have diabetes face potential liability.

When it's legitimate: If a patient has both type 2 diabetes and obesity, the provider can prescribe Ozempic for diabetes management. Weight loss is a known beneficial effect. The prescription is for an FDA-approved indication, and Part D will cover it. The patient may lose weight as a secondary outcome, but the primary indication is diabetes.

This is not a "loophole" in the sense of exploiting a technicality. It's appropriate prescribing for a patient with both conditions. But it doesn't help Medicare patients who have obesity without diabetes.

Out-of-pocket cost breakdown for Medicare patients

For Medicare beneficiaries who don't have Part D coverage for Wegovy, the options are limited.

Option 1: Pay cash at the pharmacy.

• Wegovy 2.4 mg pen (4-week supply): $1,349 to $1,430 depending on pharmacy
• Annual cost: $16,188 to $17,160
• GoodRx coupons typically reduce this to $1,200 to $1,290 per month
• Novo Nordisk savings card does not apply to Medicare patients (federal anti-kickback statute prohibits manufacturer copay assistance for government program beneficiaries)

Option 2: Switch to a Part D plan that covers Wegovy.

• Only possible during Annual Enrollment Period (October 15 to December 7) or a Special Enrollment Period
• New coverage starts January 1 of the following year
• Expected out-of-pocket: $3,600 to $5,200 annually depending on plan structure and coverage gap

Option 3: Enroll in a Medicare Advantage plan with obesity coverage.

• Same enrollment period restrictions as Option 2
• Expected out-of-pocket: $1,800 to $3,000 annually if the plan includes Wegovy in a supplemental benefit
• May require participation in a structured weight-management program

Option 4: Use compounded semaglutide.

• Not covered by Medicare Part D (compounded medications are excluded from Part D formularies)
• Patient pays out of pocket: $179 to $279 per month through FormBlends
• Annual cost: $2,148 to $3,348
• No prior authorization, no formulary restrictions, no coverage gap

Cost comparison table:

Option	Monthly cost	Annual cost	Medicare coverage
Wegovy cash price	$1,349	$16,188	No
Wegovy with Part D (average)	$300 to $450	$3,600 to $5,400	Yes (if plan covers)
Wegovy with Medicare Advantage obesity benefit	$150 to $250	$1,800 to $3,000	Yes (select plans)
Compounded semaglutide (FormBlends)	$179 to $279	$2,148 to $3,348	No
Ozempic for diabetes (Part D covered)	$50 to $150	$600 to $1,800	Yes (diabetes indication only)

For most Medicare patients without diabetes, compounded semaglutide represents the most affordable option that doesn't require waiting until the next enrollment period.

The compounded semaglutide alternative for Medicare beneficiaries

Compounded semaglutide is the same active pharmaceutical ingredient as Wegovy, prepared by a state-licensed compounding pharmacy in response to an individual prescription. It's not FDA-approved, not covered by Medicare Part D, and not interchangeable with brand-name products.

Why Medicare patients choose compounded semaglutide:

1. Immediate access. No waiting for open enrollment. Start within days of provider consultation.
2. Predictable cost. $179 to $279 per month, no deductible, no coverage gap, no prior authorization.
3. No diagnosis restrictions. Prescribed based on clinical appropriateness, not insurance formulary rules.
4. Dose flexibility. Providers can titrate to the optimal dose for the individual patient, including doses between standard Wegovy increments.

Trade-offs compared to brand-name Wegovy:

• Compounded semaglutide is drawn from a vial with a syringe rather than delivered via a pre-filled pen. Some patients find this less convenient.
• It's not FDA-approved. The FDA's approval process includes manufacturing oversight, stability testing, and post-market surveillance that compounded medications don't undergo.
• Compounded medications are prepared in smaller batches. Consistency between batches can vary more than with mass-manufactured products.

When compounded makes sense for Medicare patients:

• Your Part D plan doesn't cover Wegovy
• You can't afford the $1,349 monthly cash price for brand-name Wegovy
• You don't want to wait until the next enrollment period to switch plans
• You're comfortable with the trade-offs between compounded and FDA-approved medications

When brand-name Wegovy makes sense:

• Your Part D plan covers it with a copay under $200 per month
• You strongly prefer FDA-approved medications
• You want the convenience of a pre-filled pen
• You're willing to navigate prior authorization and formulary restrictions

FormBlends connects Medicare-eligible patients with licensed providers who can evaluate whether compounded semaglutide is clinically appropriate. The consultation is typically $49, and the provider discusses the patient's medical history, current medications, and weight-loss goals before prescribing.

How to verify your specific Part D plan's Wegovy coverage

Step 1: Find your plan's formulary. Log in to your Part D plan's member portal or call the customer service number on your insurance card. Request the current formulary (the list of covered drugs).

Step 2: Search for semaglutide and Wegovy. Look up "semaglutide" and "Wegovy" in the formulary. Note which tier each is on. Tier 1 and 2 are typically generics and preferred brands. Tier 3 and 4 are non-preferred brands. Tier 5 is specialty medications.

Step 3: Check for restrictions. Look for letters next to the drug name:

• PA = prior authorization required
• QL = quantity limit
• ST = step therapy (must try other medications first)

Step 4: Calculate your expected cost. Your plan's Summary of Benefits document (available in your member portal) lists the copay or coinsurance for each tier. For Tier 5 specialty drugs, it's typically 25% to 33% coinsurance.

Multiply the coinsurance percentage by the negotiated price. Call the plan to ask for the negotiated price for Wegovy if it's not listed in the formulary.

Step 5: Understand prior authorization requirements. If PA is required, ask the plan for the specific criteria. Common requirements:

• BMI over 30 (or over 27 with weight-related comorbidity)
• Documentation of diet and exercise attempts for at least 3 to 6 months
• No contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2)

Your provider will need to submit these documents. Approval typically takes 3 to 10 business days.

Step 6: Compare against alternatives. If your Part D copay is over $300 per month, compare against:

• Switching to a different Part D plan during the next enrollment period
• Compounded semaglutide at $179 to $279 per month
• Paying cash for Wegovy with a GoodRx coupon ($1,200 to $1,290)

This six-step verification prevents the most common surprise: discovering at the pharmacy that your plan doesn't cover Wegovy or that your copay is $450.

What most articles get wrong about Medicare obesity coverage

Most online content about Medicare and Wegovy makes one of three errors:

Error 1: Conflating "Medicare" with "Medicare Part D." Articles say "Medicare doesn't cover Wegovy" without specifying which part of Medicare. Technically accurate for Part B, misleading for Part D. The correct statement is: "Medicare Part B doesn't cover Wegovy. Some Medicare Part D plans cover it starting in 2026."

Error 2: Overstating the impact of the 2026 CMS guidance. Headlines like "Medicare Now Covers Weight-Loss Drugs" appeared after the January 2026 guidance. The guidance permits coverage; it doesn't mandate it. As of April 2026, fewer than one-third of Part D plans have added Wegovy to their formularies. Most Medicare beneficiaries still don't have coverage.

Error 3: Ignoring the coverage gap. Articles that quote the Tier 5 coinsurance percentage (25% to 33%) without mentioning the coverage gap create a false impression of annual cost. A patient who calculates $300 per month based on 25% coinsurance expects $3,600 annually. The actual cost is $4,800 to $5,200 because of the gap-phase cost-sharing structure.

The correct framing: Medicare Part B never covers Wegovy. Medicare Part D may cover it if your specific plan added it to the 2026 formulary, but most plans haven't. If your plan does cover it, expect $3,600 to $5,400 in annual out-of-pocket costs after accounting for the deductible and coverage gap. For many Medicare patients, compounded semaglutide at $2,148 to $3,348 annually is the more accessible option.

FAQ

Does Medicare Part B cover Wegovy? No. Medicare Part B does not cover Wegovy under any circumstances. Federal law (Social Security Act Section 1862) explicitly excludes weight-loss drugs from Part A and Part B coverage. This exclusion applies regardless of BMI, comorbidities, or medical necessity.

Does Medicare Part D cover Wegovy? Some Medicare Part D plans cover Wegovy starting in 2026, but coverage is not universal. As of April 2026, about 23% of standalone Part D plans and 31% of Medicare Advantage plans with Part D include Wegovy in their formularies. Check your specific plan's formulary to confirm.

Why doesn't Medicare cover weight-loss medications? The Social Security Act, passed in 1965, excludes drugs used for weight loss from Medicare coverage. This was a cost-control measure when Medicare was created. Changing this exclusion requires an act of Congress. The Treat and Reduce Obesity Act would remove the exclusion but has not passed as of 2026.

Can I get Wegovy covered if I have diabetes and obesity? If you have type 2 diabetes, your Part D plan likely covers Ozempic (semaglutide for diabetes). Ozempic and Wegovy contain the same active ingredient but are approved for different indications. Your provider can prescribe Ozempic for diabetes management, which may result in weight loss as a beneficial side effect.

How much does Wegovy cost for Medicare patients without coverage? The cash price is $1,349 to $1,430 per month at most pharmacies. With a GoodRx coupon, expect $1,200 to $1,290. The Novo Nordisk savings card does not apply to Medicare beneficiaries due to federal anti-kickback regulations.

What is the Medicare coverage gap for Wegovy? The coverage gap (donut hole) is a phase in Part D cost-sharing. After your total drug spending reaches $5,030, you enter the gap and pay 25% of the price for brand-name drugs until your out-of-pocket spending reaches $8,000. For Wegovy at $1,200 per month, you'd pay about $300 monthly in the gap.

Can I switch to a Part D plan that covers Wegovy? Yes, but only during the Annual Enrollment Period (October 15 to December 7) or if you qualify for a Special Enrollment Period. New coverage starts January 1 of the following year. Compare plans at Medicare.gov using the Plan Finder tool.

Is compounded semaglutide covered by Medicare? No. Medicare Part D excludes compounded medications from coverage. Patients pay out of pocket. FormBlends compounded semaglutide costs $179 to $279 per month, significantly less than the $1,349 cash price for brand-name Wegovy.

Do Medicare Advantage plans cover Wegovy differently than standalone Part D plans? Some Medicare Advantage plans offer enhanced weight-management benefits that include GLP-1 coverage with lower copays than typical Part D specialty tiers. About 8% of Medicare Advantage plans in 2026 include such benefits. These plans often require participation in a structured weight-loss program.

What if my Part D plan denies coverage for Wegovy? You can request a formulary exception if your provider documents medical necessity. The approval rate for exceptions is low (typically under 20%). Alternatives include switching plans during open enrollment, paying cash, or using compounded semaglutide.

Can I use the Novo Nordisk savings card with Medicare? No. Federal law (the Anti-Kickback Statute) prohibits pharmaceutical manufacturers from offering copay assistance to Medicare, Medicaid, and other government program beneficiaries. The savings card is only available to patients with commercial insurance.

Will Medicare ever cover Wegovy under Part B? Only if Congress passes legislation removing the weight-loss drug exclusion from the Social Security Act. The Treat and Reduce Obesity Act has been introduced multiple times since 2013 but has not passed. There is no timeline for when or if this might change.

Sources

1. Kaplan RM et al. The Treat and Reduce Obesity Act: A Missed Opportunity for Medicare Beneficiaries. Health Affairs. 2024.
2. Centers for Medicare & Medicaid Services. HPMS Memo 2026-001: Part D Coverage of Anti-Obesity Medications. January 2026.
3. Cubanski J et al. Medicare Part D Coverage of Anti-Obesity Medications in 2026. Kaiser Family Foundation. 2026.
4. Johnson A et al. Medicare Advantage Supplemental Benefits for Obesity Management. Avalere Health. 2026.
5. Social Security Act, Section 1862(a)(1)(A). Exclusions from Coverage and Medicare as Secondary Payer.
6. Novo Nordisk. Wegovy Prescribing Information. Revised 2024.
7. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
8. Centers for Medicare & Medicaid Services. Medicare Part D Coverage Determination and Appeals Guidance. 2025.
9. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.
10. U.S. Department of Health and Human Services Office of Inspector General. Fraud and Abuse Laws: Anti-Kickback Statute. 2023.
11. GoodRx Research Team. Average Retail Prices for GLP-1 Receptor Agonists. Q1 2026.
12. Blonde L et al. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan. Endocrine Practice. 2022.
13. Centers for Medicare & Medicaid Services. 2026 Medicare Part D Benefit Parameters. Federal Register. 2025.
14. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Saxenda are registered trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Medicare is a registered trademark of the U.S. Department of Health and Human Services. GoodRx is a registered trademark of GoodRx Holdings, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these entities.